Takeover Target or Potential Buyer? Analysts Speculate on Biogen (BIIB)’s Future After Big Stock Drop
Sanofi (SNY) and Regeneron (REGN) Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal
Allergan (AGN) Could Set its Sights on Another Transformative M&A Deal With Biogen (BIIB), Amgen (AMGN) or AbbVie (ABBV)
Analysts Wait With Bated Breath for Gilead (GILD) Q2 Results, Possible Acquisition News
Allergan (AGN) Considers Breaking Up Into Two Businesses Months After Actavis (ACT) Merger
Progenics Pharmaceuticals, Inc. (PGNX) Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma And Paraganglioma
FibroGen, Inc. (FGEN) Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy
Mallinckrodt (MNK) Divests Contrast Media Biz to Guerbet (GBT) For $270 Million
Report Shows Gilead (GILD) Creates $3.5 Million per Employee
When Her Daughter Was Diagnosed With A Rare Disease, This Accountant Started A Biotech
Teva (TEVA) Snaps Up Allergan (AGN) Generics for $40.5 Billion, Ends Pursuit of Mylan (MYL)
Allergan (AGN) Coughs Up $560 Million Cash for Naurex
AstraZeneca PLC (AZN) Divests Yet Another Drug, This Time to Sanofi (SNY) for $300 Million
More Shakeups at Aegerion (AEGR) as CEO and COO Resign
Oncobiologics Secures $31 Million Financing
Bellerophon Therapeutics (BLPH) Heart Device Flunks Key Study
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s
Roche (RHHBY) Terminates $1 Billion Cancer Deal With Molecular Partners AG
See All News >
//-->